In an order posted by the U.S. Court of Appeals for the Federal Circuit, the court affirmed a win for Amneal Pharmaceuticals (AMRX) in a decision that would remove patents related to Teva Pharmaceuticals’ (TEVA) ProAir HFA inhaler from the Food and Drug Administration’s Orange Book. Amneal plans to market a generic version of the inhaler and had argued that Teva’s patents were incorrectly included on the FDA list. The order posted to the site of the court states: “Teva appealed, and we stayed the district court’s order pending our resolution of this case. We now lift the stay and affirm the district court’s delisting order.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TEVA:
- PBMs took payments from manufacturers to allow free flow of opioids, NYT reports
- Teva price target raised to $28 from $26 at UBS
- Teva price target raised to $28 from $25 at Barclays
- TD says Spyre has ‘superior TL1A program’ after Teva data
- Teva and Sanofi (SNY) Jump amid Impressive Drug Results
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
